Vanda Pharmaceuticals Inc (Nasdaq: VNDA), a global biopharmaceutical company, announced its financial results for the full year ended 31 December 2020 on Wednesday.

The company reported income before taxes at USD31.7m in 2020 compared to USD29m in 2019.

The firm posted net income of USD23.3m in 2020, compared to net income of USD115.6m in 2019. It reported diluted net income per share of USD0.42 in 2020 compared to diluted net income per share of USD2.11 in 2019.

'I am very proud of the significant accomplishments we realised during this challenging year,' said Mihael H Polymeropoulos, Vanda's MD, president and CEO.